Literature DB >> 9707487

Estrogen improves performance of reinforced T-maze alternation and prevents the amnestic effects of scopolamine administered systemically or intrahippocampally.

A J Fader1, A W Hendricson, G P Dohanich.   

Abstract

In a previous study, administration of high doses of estradiol benzoate (100 microgram/kg for 3 days im) to ovariectomized Long-Evans rats counteracted impairments of reinforced T-maze alternation induced by systemic administration of scopolamine, a muscarinic receptor blocker. In the current study, daily administration of lower doses of estradiol benzoate (5 microgram/kg for 3 weeks sc) increased the number of correct reinforced alternations during T-maze acquisition in ovariectomized rats compared to oil-treated controls and prevented impairments of reinforced alternation induced by injection of scopolamine hydrobromide (0.2 mg/kg ip). Furthermore, scopolamine (20 microgram) delivered bilaterally to the dorsal hippocampus reduced reinforced T-maze alternation in ovariectomized rats previously trained to complete this task while daily treatment with estradiol benzoate (5 microgram/kg sc) for 1 week prior to scopolamine infusion counteracted this impairment. In summary, physiological levels of estrogen improved performance during acquisition of reinforced T-maze alternation and prevented impairments induced by scopolamine administered systemically or intrahippocampally. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707487     DOI: 10.1006/nlme.1998.3820

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  39 in total

1.  Castration in rats impairs performance during acquisition of a working memory task and exacerbates deficits in working memory produced by scopolamine and mecamylamine.

Authors:  Jill M Daniel; Peter J Winsauer; Joseph M Moerschbaecher
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

2.  Ovarian hormone loss impairs excitatory synaptic transmission at hippocampal CA3-CA1 synapses.

Authors:  Wendy W Wu; Damani N Bryant; Daniel M Dorsa; John P Adelman; James Maylie
Journal:  J Neurosci       Date:  2013-10-09       Impact factor: 6.167

Review 3.  Estrogens and age-related memory decline in rodents: what have we learned and where do we go from here?

Authors:  Karyn M Frick
Journal:  Horm Behav       Date:  2008-09-16       Impact factor: 3.587

4.  Differential effects of acute progesterone administration on spatial and object memory in middle-aged and aged female C57BL/6 mice.

Authors:  Michael C Lewis; Patrick T Orr; Karyn M Frick
Journal:  Horm Behav       Date:  2008-05-27       Impact factor: 3.587

Review 5.  Aging, estrogens, and episodic memory in women.

Authors:  Victor W Henderson
Journal:  Cogn Behav Neurol       Date:  2009-12       Impact factor: 1.600

6.  An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms.

Authors:  J I Acosta; R Hiroi; B W Camp; J S Talboom; H A Bimonte-Nelson
Journal:  Brain Res       Date:  2013-01-16       Impact factor: 3.252

Review 7.  Tracking the estrogen receptor in neurons: implications for estrogen-induced synapse formation.

Authors:  B McEwen; K Akama; S Alves; W G Brake; K Bulloch; S Lee; C Li; G Yuen; T A Milner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 8.  Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury.

Authors:  E B Engler-Chiurazzi; C M Brown; J M Povroznik; J W Simpkins
Journal:  Prog Neurobiol       Date:  2016-02-15       Impact factor: 11.685

Review 9.  Estrogen therapy and cognition: a review of the cholinergic hypothesis.

Authors:  Robert B Gibbs
Journal:  Endocr Rev       Date:  2009-12-17       Impact factor: 19.871

10.  Sex-specific effects of gonadectomy and hormone treatment on acquisition of a 12-arm radial maze task by Sprague Dawley rats.

Authors:  Robert B Gibbs; David A Johnson
Journal:  Endocrinology       Date:  2008-02-21       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.